摘要
目的探讨睾酮联合索利那新治疗良性前列腺增生症(BPH)患者电切术后早期出现下尿路症状(LUTS)的临床效果。方法选取2017年1~9月肇庆市第二人民医院收治的BPH患者中,血清总睾酮(TT)低于正常范围、行经尿道前列腺电切术(TURP)术后第7天拔除尿管后出现LUTS的患者26例,随机分为实验组和对照组,每组各13例。实验组予睾酮补充联合索利那新口服治疗,对照组单纯予睾酮补充,疗程均为30 d。比较两组服药前、服药后第14天及第30天,前列腺特异抗原(PSA)、TT、国际前列腺症状评分(IPSS)、生活质量指数评分(QOL)、膀胱过度活动症状评分(OABSS)、最大尿流率(Qmax)、残余尿量(RU)和直肠指诊(DRE)的结果。结果治疗前两组各指标比较,差异均无统计学意义(P>0.05)。服药前、服药后第14天两组组内比较,IPSS、QOL评分差异有统计学意义(P<0.05);服药前、服药后第30天两组组内比较,TT、Qmax、IPSS、QOL及OABSS指标差异均有统计学意义(P<0.05)。组间比较显示,服药后第14天两组各指标比较,差异均无统计学意义(P>0.05);而服药后第30天实验组IPSS、QOL及OABSS评分均高于对照组,差异均有统计学意义(P<0.05)。两组患者服药第14天及第30天直肠指诊均未及前列腺硬结。结论 M受体阻滞剂索利那新联合睾酮补充能有效缓解TURP术后出现的LUTS症状,对于睾酮水平低下、伴有LUTS的BPH患者,可予睾酮补充联合M受体阻滞剂治疗。
Objective To investigate the clinical efficacy of Testosterone supplement combining with Solifenacin in the treatment for early stage of lower urinary tract symptoms（LUTS） after transurethral resection of the prostate（TUPP） for benign prostatic hyperplasia（BPH） patients. Methods Twenty-six cases with BPH treated in the Second People＇s Hospital in Zhaoqing City from January 2017 to September 2017, that serum total testosterone（TT） was lower than normal range, and post TURP for 7 d with LUTS after removal of catheter were selected and they were randomly divided into experimental group and control group, with 13 cases in each group. The experimental group was applicated with Testosterone supplement and Solifenacin,and the control group was only supplemented with Testosterone supplement. The treatment course was 30 days. Prostate specific antigen（PSA）, TT, International prostate symptom score-Quality of life（IPSS-QOL） score, overactive bladder symptom score（OABSS）, the maximum flow rate（Qmax）, residual urine（RU） and digital rectal examination between the two groups were compared before treatment, on 14 th day and 30 th day after treatment. Results Before treatment, the indices above between the two groups had no statistically significant differences（P〈0.05）. There was a statistically significant difference in the IPSS-QOL scores in the two groups before and 14 th day after treatment（P〉0.05）. There were significant differences in TT, Qmax, IPSS-QOL and OABSS in the two groups before and in 30 th day after treatment（P〈0.05）. On 14 th day after treatment, there was no significant difference between the two groups in the indices above（P〉0.05）. On 30 th day after treatment, the scores of IPSS-QOL and OABSS in the experimental group were all higher than those in the control group, the differences were statistically significant（P〈0.05）. On 14 th and 30 th day after treatment, both groups were not touched prostatic induration in rectal digital examination. C
作者
陈深泉
苏玖雄
黎鉴飞
吴保忠
刘明建
杨帝宽
CHEN Shenquan;SU Jiuxiong;LI Jianfei;WU Baozhong;LIU Mingjian;YANG Dikuan(Department of Urinary Surgery,the Second People＇s Hospital in Zhaoqing City,Guangdong Province,Zhaoqing 526060,China;Department of Andrology,the Second People＇s Hospital in Zhaoqing City,Guangdong Province,Zhaoqing 526060,China)
出处
《中国医药导报》
CAS
2018年第24期58-62,共5页
China Medical Herald
基金
广东省肇庆市科技创新计划项目(2016040301)
关键词
睾酮补充
索利那新
经尿道前列腺电切术
下尿路症状
Testosterone supplement
Solifenaein
Transurethral Resection of the Prostate
Lower urinary tract symptoms
